XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and hepatocellular carcinoma risk by Long, Xi Dai et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cancer
Open Access Research article
XPD codon 312 and 751 polymorphisms, and AFB1 exposure, and 
hepatocellular carcinoma risk
Xi Dai Long*†1, Yun Ma†2, Yun Feng Zhou†1, Jin Guang Yao†3, Fu Zhi Ban4, 
Yong Zhi Huang1 and Bing Cheng Huang1
Address: 1Department of Pathology, Youjiang Medical College for Nationalities, Baise, Guangxi Zhuang Autonomous Region, PR China, 
2Department of Pathology, Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, PR China, 3Department of Medicine, 
Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi Zhuang Autonomous Region, PR China and 4Department of 
Medical Test, Affiliated Southwest Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi Zhuang Autonomous Region, PR China
Email: Xi Dai Long* - xiaolonglong200166@yahoo.com.cn; Yun Ma - yunandama@hotmail.com; 
Yun Feng Zhou - zhyf200166@yahoo.com.cn; Jin Guang Yao - jingangyao1@yahoo.cn; Fu Zhi Ban - fuzhiban@yahoo.cn; 
Yong Zhi Huang - yongzhihuang@yahoo.cn; Bing Cheng Huang - huangbingcheng49@yahoo.com.cn
* Corresponding author    †Equal contributors
Abstract
Background: Genetic polymorphisms in DNA repair genes may influence individual variation in
DNA repair capacity, which may be associated with risk of hepatocellular carcinoma (HCC) related
to the exposure of aflatoxin B1 (AFB1). In this study, we have focused on the polymorphisms of
xeroderma pigmentosum complementation group D (XPD) codon 312 and 751 (namely
Asp312Asn and Lys751Gln), involved in nucleotide excision repair.
Methods: We conducted a case-control study including 618 HCC cases and 712 controls to
evaluate the associations between these two polymorphisms and HCC risk for Guangxi population
by means of TaqMan-PCR and PCR-RFLP analysis.
Results: We found that individuals featuring the XPD genotypes with codon 751 Gln alleles
(namely XPD-LG or XPD-GG) were related to an elevated risk of HCC compared to those with
the homozygote of XPD codon 751 Lys alleles [namely XPD-LL, adjusted odds ratios (ORs) were
1.75 and 2.47; 95% confidence interval (CIs) were 1.30-2.37 and 1.62-3.76, respectively]. A gender-
specific role was evident that showed an higher risk for women (adjusted OR was 8.58 for XPD-
GG) than for men (adjusted OR = 2.90 for XPD-GG). Interestingly, the interactive effects of this
polymorphism and AFB1-exposure information showed the codon 751 Gln alleles increase the risk
of HCC for individuals facing longer exposure years (Pinteraction = 0.011, OR = 0.85). For example,
long-exposure-years (> 48 years) individuals who carried XDP-GG had an adjusted OR of 470.25,
whereas long-exposure-years people with XDP-LL were at lower risk (adjusted OR = 149.12).
However, we did not find that XPD codon 312 polymorphism was significantly associated with
HCC risk.
Conclusion: These findings suggest that XPD Lys751Gln polymorphism is an important modulator
of AFB1 related-HCC development in Guangxi population.
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Background
Aflatoxin B1 (AFB1), the most common cause of high
incidence rates of hepatocellular carcinoma (HCC) in
Guangxi population [1,2], is an important chemical car-
cinogen and can induce AFB1-DNA adducts formation
and cause DNA strand break, DNA base damage, and oxi-
dative damage that may ultimately lead to cancer [3].
AFB1-induced DNA damage can be repaired by base exci-
sion repair (BER), strand break repair pathway, and nucle-
otide excision repair (NER) [4,5].
We have previously reported a relationship between HCC
risk and allelic variations in the X-ray repair cross-comple-
menting group 1 (XRCC1) and XRCC3 genes which are
involved in BER and strand break repair pathway [6,7]. In
this study, we focused on the xeroderma pigmentosum
complementation group D (XPD) gene, which is one of
the seven genetic complementation groups encoding for
proteins involved in the NER pathway [5,8,9]. The two
XPD polymorphic loci that have been of particular inter-
est in molecular epidemiology studies are the Asp312Asn
polymorphism in exon 10 and the Lys751Gln polymor-
phism in exon 23 [10]. Some studies have shown these
two polymorphisms may be associated with decreased
DNA repair capacity [11-13], increased frequency of p53
mutations [14-17], and increased tumor risk [13,18-30].
Therefore, we specifically conducted a hospital-based
case-control study to examine whether these two poly-
morphisms modify the risk of HCC among Guangxi pop-
ulation from an AFB1 exposure area.
Methods
Study Subjects
HCC patients (n = 635) and control individuals (n = 712),
who were residents of Guangxi Zhuang Autonomous
Region from AFB1 exposure areas, were recruited from
Affiliated Hospitals of the two main medical colleges in
the Southwestern Guangxi (namely Guangxi Medical Uni-
versity and Youjiang Medical College for Nationalities)
between January 2006 and August 2008. Cases and con-
trols accepted to be enrolled in a proportion of 100%. The
part of HCC patiens (n = 17) was excluded from this study
because of the insufficient DNA samples. Thus, a total of
618 HCC cases, including 119 patients previously studied
[6,31], were included in present analysis. Cases included
in present study, representing for a significant portion of
HCCs from Guangxi population, were identified through
hepato surgery, hepato pathology, oncology, hepatology
centres and through cancer registries, and confirmed by
histopathological diagnosis in 100% of the HCC cases.
During the same period, controls without clinical evi-
dence of liver diseases (including 122 subjects previously
studied [6]) were randomly selected from a pool of
healthy volunteers that visited the general health check-up
center of the same hospitals because of their routine
scheduled physical exams supported by local govern-
ments.
To control the effects of confounders which were likely
risk factors for Guangxiese HCC, controls were frequently
matched to cases based on ethnicity (Han, Minority), sex,
age (± 5 years), and hepatic B virus (HBV) and HCV infec-
tion. These having hepatitis B surface antigen (HBsAg)-
positive and anti-HCV-positive in their peripheral serum
were defined as groups infected HBV and HCV. With
informed consent, the characteristic information of all
study subjects, including sex, age, ethnicity, HBsAg and
anti-HCV, were ascertained as described previously [7], at
the same time 4 ml of peripheral blood was also collected.
The study protocol was been carried out in accordance
with "Ethical Principles for Medical Research Involving
Human Subjects" (World Medical Association Declara-
tion Of Helsinki, 2004) and approved by Institutional
review boards from Guangxi Cancer Institute, and
Guangxi Government Medical Research Council.
AFB1 Exposure
AFB1-exposure information included exposure-years and
levels. In Guangxi, because food consumption types are
relatively simple and limited corn, peanut, and rice, and
AFB1 mainly contaminates these poorly stored food, espe-
cially, corn and peanut, the years of participants having
food contaminated by AFB1 were defined as AFB1-expo-
sure years for subjects. Cumulative AFB1 exposure-years
were calculated by the following formula: exposure-years
= (age - migration-years), where migration-years were
defined as the years a person lived in non-exposure region
of AFB1 (described in our previously published study [7]).
To analyze, AFB1-exposure years were divided into three
groups: short (< 40 years), medium (40 - 48 years), and
long (> 48 years), according to the value of AFB1-exposure
years, with two cutoff points of 40 and 48 years, the
median exposure years among controls and cases.
In this study, we evaluated the AFB1-exposure levels by
means of AFB1-DNA adducts levels of DNA samples from
all subjects' peripheral blood leukocytes resulting from
the fact that the DNA samples of liver tissue were not
obtained from the controls. DNA was extracted from leu-
kocyte samples by standard phenol-chloroform extrac-
tion, treated with 15 mM Na2CO3 and 30 mM NaHCO3
(pH 9.6) for 2 hrs to convert any N-7 adduct to AFB1-FAPy
adducts, precipitated with 2.5 volumes of 95% ethanol,
and then redissolved in 10 mM Tris-HCl (pH 7.0). The
DNA samples were reprecipitated, dissolved in 1 × PBS,
and denatured by boiling for 3 min and the AFB1-FAPy
adducts were quantitated by competitive enzyme-linked
immunosorbent assay (ELISA) using monoclonal anti-
body 6A10 (Novus Biologicals LLC, catalog # NB600-BMC Cancer 2009, 9:400 http://www.biomedcentral.com/1471-2407/9/400
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443) and 50 μg of DNA as described by Hsieh LL, et al
[32]. The percent of inhibition was calculated by compar-
ison with the nonmodified heat-denatured calf thymus
DNA control (R&D Systems, Inc., catalog # 9600-5-D).
DNA samples were assayed at 50 μg/well and quantitated
relative to an imidazole ring-opened AFB1-DNA standard,
which has a modification level of 4 adducts/10 nucle-
otides. Values about 10% inhibitions were corresponded
to 0.25 μmol/mol DNA. Each sample was measured in
triplicate on the three different assay dates and had a var-
iability of less than 10%. Adduct levels were ascertained
according to the average of three measures. The quality
control for adduct assays was administered by blank and
positive controls. In order to analyze, AFB1-DNA adduct
levels were divided into three groups: low level (≤ 1.00
μmol/mol DNA), medium level (1.01 - 2.00 μmol/mol
DNA), and high level (≥ 2.01 μmol/mol DNA), according
to the value of AFB1-DNA adduct levels, with two cutoff
points of 1.00 and 2.00 μmol/mol DNA, the average
adducts levels among controls and cases.
Genotyping
Gene polymorphism analysis of XPD Lys751Gln was
typed by using the TaqMan-PCR on iCycler iQ™ real-time
PCR detection system (iQ5, Bio-Rad). The primers were:
5'-AGT CAC CAG GAA CCG TTT ATG G-3' and 5'-TCT
GTT CTC TGC AGG AGG ATC-3' (TaKaRa€). The probes
were: 5'-HEX-CTC TAT CCT CTG CAG CG-TAMRA-3' and
5'-FAM-TAT CCT CTT CAG CGT CT-TAMRA-3'(TaKaRa).
PCR reactions were run in a 25 μl final volume containing
1 × Premix Ex TaqTM(TaKaRa, catalog # DRR039A), 0.2
μM of each probe, 0.2 μM of each primer, and 50 - 100 ng
of genomic DNA. Cycling conditions were 95°C for 30 s,
and 50 cycles of 95°C for 10 s and 60°C for 1 min. Con-
trols were included in each run and repeated genotyping
of a random 10% subset yielded 100% identical geno-
types. Data analysis for allele discrimination was per-
formed with the iCycler iQ software. While Gene
polymorphism analysis of XPD Asp312Asn was detected
by using a previously published PCR-RFLP method [11].
Statistical Analysis
All statistical analyses were done using the statistical pack-
age for social science (SPSS) version 11.5 (SPSS Institute,
Chicago, IL). The Pearson χ2 test was used to test for dif-
ferences between the cases and the control subjects in the
distribution of gender, age, ethnicity, HBV and HCV infec-
tion, AFB1-exposure information, and XPD genotypes.
The odds ratio (OR) and the 95% confidence interval (CI)
were calculated as an estimate of relative risk. Uncondi-
tional multivariate logistic regression was used to control
for possible confounding by age, gender, ethnicity, HBV
and HCV infection, and AFB1-exposure information,
where appropriate, and when examining interactions
between the polymorphisms and AFB1-exposure informa-
tion (including exposure years and levels). Interaction was
tested using a multiplicative interaction term included in
the multivariate model. Joint effects between genotypes
and exposure information were assessed by using the full
regression model[33]. A P-value of < 0.05 was considered
statistically significant.
Results
Demographic and etiologic characteristics for subjects
There were no significant differences for sex, age, ethnic-
ity, HBsAg and anti-HCV status (P > 0.05; Table 1), which
suggested HCC patients' data are comparable with con-
trols'.
AFB1 exposure and HCC risk
Table 2 summarized AFB1-exposure information of all
study population. We found that AFB1-exposure years
(median) were longer among the cases (48 years) than the
controls (40 years) and the risk of HCC gradually
increased with the increasing exposure years (P < 0.01).
We also found that the levels of AFB1-DNA adducts were
positively associated with HCC risk (adjusted ORs were
2.11 and 6.23 for medium- and high-level adducts,
respectively). These results were consistent with our previ-
ously published data [6,7]. Additionally, we also analyzed
the association between AFB1-DNA adduct levels of
peripheral blood leukocytes and those of the cancerous
tissue of 119 HCC patients previously studied [31]. The
results showed AFB1-DNA adduct levels of the HCC can-
cerous tissue were positively and linearly related to
peripheral blood leukocytes' adduct levels (data not
Table 1: Demographic and etiologic characteristics of HCC cases 
and controls
Controls Cases
No. (%) No. (%) χ2 Two-sided P
Sex 1.945 0.163
Male 540 (75.8) 448 (72.5)
Female 172 (24.2) 170 (27.5)
Age(years)a 2.672 0.263
< 35 86 (12.1) 58 (9.4)
35-65 554 (77.8) 500 (80.9)
> 65 72 (10.1) 60 (9.7)
Ethnicity 0.891 0.345
Han 318 (44.7) 292 (47.2)
Minority 394 (55.3) 326 (52.8)
HBV infection 0.354 0.552
HBsAg (+) 508 (71.3) 450 (72.8)
HBsAg (-) 204 (28.7) 168 (27.2)
HCV infection 0.049 0.825
Anti-HCV (+) 128 (18.0) 114 (18.4)
Anti-HCV (-) 584 (82.0) 504 (81.6)
a The mean ± S.E. ages were 49.31 ± 0.45 and 49.15 ± 0.43 for cases 
and controls, respectively.BMC Cancer 2009, 9:400 http://www.biomedcentral.com/1471-2407/9/400
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shown), which suggested that the levels of peripheral
blood leukocytes' DNA adducts were representative of the
tissues' DNA-adduct levels.
XPD polymorphisms and HCC risk
The genotypic distribution of XPD Asp312Asn and
Lys751Gln for both cancer cases and controls were shown
in Table 3. The frequencies of the codon 312 Asn allele
and codon 751 Gln allele among cases (0.26 and 0.38,
respectively) were higher than among controls (0.22 and
0.22, respectively). Genotypic distributions of these two
loci in controls were in Hardy-Weinberg equilibrium
[Chi-square (P-values) were 1.56 (0.458) and 2.704
(0.259) for codon 312 and 751 genotypes, respectively,
data not shown]. However, logistic regression analyses
showed that only the codon Lys751Gln polymorphism
was significantly associated with the increasing risk of
HCC. The adjusted OR for HCC for those individuals car-
rying the heterozygotes for codon 751 Lys and Gln allele
(XPD-LG) compared with those exhibiting featuring the
homozygote for Lys alleles (XPD-LL) was 1.75 (95% CI,
1.30 - 2.37), and the corresponding OR for those featuring
the homozygote for Gln alleles (XPD-GG) was 2.47 (95%
CI, 1.62 - 3.76), which showed the risk of HCC was asso-
ciated with the number of codon 751 Gln alleles.
XPD codon 751 polymorphism and HCC risk stratified by 
HBV infection, HCV infection, and gender
To evaluate the modification of gender on the effect of risk
genotypes (adjusted OR > 1) of XPD codon 751, we inves-
tigated the risk for HCC associated with the genetic poly-
morphism separately among female group and among
male participants (Table 4). The results demonstrated that
the genotypes with codon 751 Gln alleles were related to
a higher risk of HCC for women than for men (Pinteraction
< 0.01, OR = 0.43). When we compared the XPD-GG ver-
Table 2: AFB1 exposure and the risk of HCC
Controls HCCs
AFB1 exposure n % n % OR (95% CI) Adjusted OR (95% CI) Ptrend
AFB1-exposure yearsa, b
Short 378 53.1 130 21.0 Reference Reference
Medium 197 27.7 196 31.7 2.89 (2.19-3.83) 9.08(6.07-13.57)c < 0.001
Long 137 19.2 292 47.2 6.20 (4.66-8.24) 156.03(77.83-312.77)c < 0.001
AFB1-DNA adducts levelsd, e
Low 380 53.4 153 24.8 Reference Reference
Medium 209 29.4 172 27.8 2.04(1.55-2.69) 2.11(1.54-2.90)f < 0.001
High 123 17.3 293 47.4 5.92(4.46-7.84) 6.23(4.48-8.67)f < 0.001
a The Median for AFB1-exposure years were 48 years and 40 years for cases and controls, respectively.
b AFB1-exposure years were: < 40 years for short exposure; 40 - 48 years for medium exposure; > 48 years for long exposure.
c Adjusted for age, sex, ethnicity, HBsAg, anti-HCV, and AFB1-DNA adducts levels.
d The mean ± S.E. level of AFB1-DNA adducts is 1.97 ± 0.05 and 1.04 ± 0.02 μmol/mol DNA for cases and controls, respectively.
e Adduct levels were: ≤ 1.00 μmol/mol DNA for low level; 1.01 -- 2.00 μmol/mol DNA for medium; ≥ 2.01 μmol/mol DNA for high level.
f Adjusted for age, sex, ethnicity, HBsAg, anti-HCV, and AFB1-exposure years.
Table 3: The polymorphisms of XPD and the risk of HCC
Controls HCCs
XPD genotype n % n % OR (95% CI) Adjusted OR (95% CI)a Ptrend
XPD codon Asp312Asn
DDb 453 63.6 364 58.9 Reference Reference
DNb 200 28.1 190 30.7 1.18(0.92-1.51) 1.12(0.83-1.51) 0.460
NNb 59 8.3 64 10.4 1.35(0.93-1.97) 0.89(0.56-1.41) 0.620
XPD codon Lys751Gln
LLc 464 65.2 272 44.0 Reference Reference
LGc 187 26.3 222 35.9 2.03(1.58-2.59) 1.75(1.30-2.37) < 0.001
GGc 61 8.6 124 20.1 3.47(2.47-4.88) 2.47(1.62-3.76) < 0.001
a Adjusted for age, sex, ethnicity, HBsAg, anti-HCV, AFB1-exposure years, and AFB1-DNA adduct levels.
b DD, DN, and NN represented the homozygotes of XPD codon 312 Asp alleles, the heterozygotes of XPD codon 312 Asp and Asn allele, and the 
homozygotes of XPD codon 312 Asn alleles, respectively.
c LL, LG, and GG represented the homozygotes of XPD codon 751 Lys alleles, the heterozygotes of XPD codon 751 Lys and Gln allele, and the 
homozygotes of XPD codon 751 Gln alleles, respectively.BMC Cancer 2009, 9:400 http://www.biomedcentral.com/1471-2407/9/400
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sus XPD-LL, the adjusted OR for women was 8.58 (95%
CI, 3.28 - 22.46), whereas the adjusted OR for men was
2.90 (95% CI, 1.99 - 4.21).
Because HBV and HCV infection are two important risk
factors for HCC among the Guangxi population, we ana-
lyzed the modified effects between these two confounders
and XPD codon 751 polymorphism on HCC risk (Table
4). Similar risk values for HCC were found among HBsAg-
positive carriers and among HBsAg-negative participants
(adjusted ORs were 1.77 and 2.01, respectively). Similar
results were also found in the stratified analysis between
among anti-HCV-positive carriers and among anti-HCV-
negative group (adjusted OR was 1.68 and 2.17, respec-
tively). Likelihood ration tests for interaction of the strat-
ified variables [including HBsAg (negative and positive),
and anti-HCV (negative and positive)] and XPD codon
751 genotypes were not statistically significant (Pinteraction
was 0.938 and 0.492 for HBV and HCV infection, respec-
tively).
Joint effects of AFB1 exposure and XPD codon 751 
polymorphism on HCC risk
To study the relationship between XPD codon 751 poly-
morphism and AFB1-exposure years in the risk for HCC,
we analyzed the AFB1-exposure years-genotypes joint
effect on HCC risk (Table 5). In this analysis, we used ref-
erence the lowest risk group: those who had the XPD-LL
and short-term AFB1-exposure years. The results showed
that increasing AFB1-exposure years consistently
increased HCC risk, moreover, this effect was more pro-
nounced among the XPD-LG or XPD-GG subjects. For
Table 4: XPD codon 751 polymorphism and HCC risk stratified by HBV infection (HBsAg- negative and positive), HCV infection (anti-
HCV- negative and positive), and gender (female and male)
Controls HCCs
n % n % OR (95% CI) Adjusted OR (95% CI)
HBsAga XPD
Negative LL 153 75.0 86 51.2 Reference Reference
LG 32 15.7 56 33.3 3.11(1.87-5.18) 2.36(1.25-4.45)b
GG 19 9.3 26 15.5 2.44(1.27-4.46) 1.42(0.60-3.36)b
LG/GG 51 25.0 82 48.8 2.86(1.85-4.43) 2.01(1.16-3.51)b
Positive LL 311 61.2 186 41.3 Reference Reference
LG 155 30.5 166 36.9 1.79(1.35-2.38) 1.52(1.08-2.16)b
GG 42 8.3 98 21.8 3.90(2.60-5.85) 2.64(1.60-4.37)b
LG/GG 197 38.8 264 58.7 2.24(1.73-2.90) 1.77(1.29-2.43)b
Anti-HCVc XPD
Negative LL 387 66.3 223 44.2 Reference Reference
LG 150 25.7 185 36.7 2.14(1.63-2.81) 1.93(1.39-2.70)d
GG 47 8.0 96 19.0 3.55(2.41-5.21) 2.93(1.82-4.72)d
LG/GG 197 33.7 281 55.8 2.48(1.94-3.17) 2.17(1.60-2.94)d
Positive LL 77 60.2 49 43.0 Reference Reference
LG 37 28.9 37 32.5 1.57(0.88-2.81) 1.28(0.70-2.34)d
GG 14 10.9 28 24.6 3.14(1.51-6.55) 2.77(1.29-5.93)d
LG/GG 51 39.8 65 57.0 2.00(1.20-3.34) 1.68(0.99-2.85)d
Sexe XPD
Female LL 133 77.3 65 38.2 Reference Reference
LG 33 19.2 81 47.6 5.02(3.04-8.30) 5.64(3.33-9.56)f
GG 6 3.5 24 14.1 8.19(3.19-21.01) 8.58(3.28-22.46)f
LG/GG 39 22.7 105 61.8 5.51(3.44-8.83) 6.12(3.72-10.05)f
Male LL 331 61.3 207 46.2 Reference Reference
LG 154 28.5 141 31.5 1.46(1.10-1.95) 1.50(1.12-2.01)f
GG 55 10.2 100 22.3 2.91(2.00-4.22) 2.90(1.99-4.21)f
LG/GG 209 38.7 241 53.8 1.84(1.43-2.38) 1.88(1.45-2.43)f
aLikelihood ration test for interaction of the stratified variable (HBsAg-negative and positive) and XPD codon 751 genotype was calculated as test 
for the heterogeneity of ORs across strata (interact term OR = 1.02, Pinteraction = 0.938).
bAdjusted for age, sex, ethnicity, anti-HCV, AFB1-exposure years, and AFB1-DNA adduct levels.
cLikelihood ration test for interaction of the stratified variable (anti-HCV-negative and positive) and XPD codon 751 genotype was calculated as test 
for the heterogeneity of ORs across strata (interact term OR = 0.87, Pinteraction = 0.492).
dAdjusted for age, sex, ethnicity, HBsAg, AFB1-exposure years, and AFB1-DNA adduct levels.
eLikelihood ration test for interaction of the stratified variable (female and male) and XPD codon 751 genotype was calculated as test for the 
heterogeneity of ORs across strata (interact term OR = 0.43, Pinteraction = 0.0001).
fAdjusted for age, ethnicity, HBsAg, anti-HCV, AFB1-exposure years, and AFB1-DNA adduct levels.BMC Cancer 2009, 9:400 http://www.biomedcentral.com/1471-2407/9/400
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example, individuals who featured long-term AFB1-expo-
sure years and carried the XPD-LG had an adjusted OR of
290.55 (95% CI, 125.56 - 672.36), whereas those who
had the XPD-GG had an adjusted OR of 470.25 (95% CI,
163.21-1354.96) relative to the reference group (Table 5).
Interestingly, we found that the interaction between gen-
otypes and AFB1-exposure years can modify the main
effects of XPD codon 751 genotypes in the multiplicative
model (Pinteraction = 0.011, OR = 0.85). Similar increasing-
risk trend was also found in the joint effective analysis
between XPD codon 751 genotypes and AFB1-DNA
adducts levels for the risk of HCC, although the multipli-
cative interaction term was not statistically significant (Pin-
teraction = 0.525, OR = 1.04, Table 6).
Discussion
To the best of our knowledge, no studies have investigated
the role of DNA-repair gene XPD for patients suffering
HCC, especially from AFB1 exposure areas. In this study,
we analyzed the association between XPD Asp312Asn and
Lys751Gln polymorphisms and the risk of HCC among
Guangxi population, from a high AFB1-exposure area. The
results showed XDP codon 312 polymorphism was not
related to HCC risk in Guangxi population. However, we
found the genotypes of XPD with codon 751 Gln allele
had a substantial association with the increasing risk of
HCC (adjusted OR 1.75 for XPD-LG; 2.47 for XPD-GG).
Interestingly, a gene-environment interactive effect was
found for those populations who had XPD codon 751
Gln alleles, and experienced dissimilar AFB1-exposure
years, whose adjusted ORs were 3.70 for XPD-GG and
short-term AFB1-exposure years; 18.52 for XPD-GG and
medium-term AFB1-exposure years; and 470.25 for XPD-
GG and long-term AFB1-exposure years (Pinteraction  =
0.011). These results may suggest that there were interac-
tions between the genetic polymorphism of XPD codon
Table 5: Joint effects of AFB1-exposure years and XPD codon 751 polymorphism on HCC risk
Controls HCCs
AFB1-exposure yearsa, b XPD genotypes n % n % OR (95% CI) Adjusted OR (95% CI)c
Short LL 255 35.8 66 10.7 Reference Reference
LG 97 13.6 40 6.5 1.59(1.01-2.52) 1.30(0.77-2.20)
GG 26 3.7 24 3.9 3.57(1.92-6.61) 3.70(1.80-7.59)
Medium LL 124 17.4 78 12.6 2.43(1.64-3.60) 8.77(5.29-14.53)
LG 47 6.6 70 11.3 5.75(3.64-9.10) 14.38 (7.26-28.48)
GG 26 3.7 48 7.8 7.13(4.12-12.35) 18.52 (10.24-33.50)
Long LL 85 11.9 128 20.7 5.82(3.96-8.55) 149.12(70.43-315.72)
LG 43 6.0 112 18.1 10.06(6.46-15.68) 290.55(125.56-672.36)
GG 9 1.3 52 8.4 22.32(10.47-47.62) 470.25(163.21-1354.96)
a From the likelihood ratio test comparing the fit of the logistic model that included the main effects of AFB1-exposure years, genotypes and all 
potential confounders with a fully parameterized model containing the interaction terms of XPD codon 751 genotypes and AFB1-exposure years 
(interact term OR = 0.85, Pinteraction = 0.011).
b AFB1-exposure years were: < 40 years for short exposure; 40 - 48 years for medium exposure; > 48 years for long exposure.
c Adjusted for age, sex, ethnicity, HBsAg, anti-HCV, and AFB1-DNA adducts levels.
Table 6: Joint effects of AFB1-DNA adducts levels and XPD codon 751 polymorphism on HCC risk
Controls HCCs
AFB1-DNA adducts levelsa, b XPD genotypes n % n % OR (95% CI) Adjusted OR (95% CI)c
Low LL 257 36.1 64 10.4 Reference Reference
LG 94 13.2 68 11.0 2.90(1.92-4.40) 3.27(2.04-5.26)
GG 29 4.1 21 3.4 2.91(1.56-5.43) 3.45(1.71-6.96)
Medium LL 153 21.5 117 18.9 3.07(2.13-4.42) 3.53(2.33-5.35)
LG 44 6.2 40 6.5 3.65(2.20-6.07) 3.56(2.01-6.30)
GG 12 1.7 15 2.4 5.02(2.24-11.25) 5.56(2.14-14.44)
High LL 54 7.6 91 14.7 6.77(4.38-10.44) 8.25(4.97-13.71)
LG 49 6.9 114 18.4 9.34(6.06-14.40) 10.42(6.29-17.28)
GG 20 2.8 88 14.2 17.67(10.12-30.85) 18.51(9.70-35.30)
a From the likelihood ratio test comparing the fit of the logistic model that included the main effects of AFB1-DNA adducts levels, genotypes and all 
potential confounders with a fully parameterized model containing the interaction terms of XPD codon 751 genotypes and AFB1-DNA adducts 
levels (interact term OR = 1.04, Pinteraction = 0.525).
b AFB1-DNA adducts levels were: ≤ 1.00 μmol/mol DNA for low; 1.01 -- 2.00 f μmol/mol DNA for medium; ≥ 2.01 μmol/mol DNA for high.
c Adjusted for age, sex, ethnicity, HBsAg, anti-HCV, and AFB1-exposure years.BMC Cancer 2009, 9:400 http://www.biomedcentral.com/1471-2407/9/400
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751 and AFB1-exposure years, and imply that this poly-
morphism may have functional significance in HCC
induced by AFB1.
HCC is one of major cancer types in Guangxi Zhuang
Autonomous Region, China [1,2]. Clinic-epidemiological
evidence suggests that the heavy AFB1 exposure via corn
and groundnut consumption, main food consumption
types for Guangxiese, is the most common cause [1,2].
Our previous studies [6,7] and present study not only sup-
ported the aforementioned studies, but also we found the
risk of HCC was associated with different AFB1-exposure
status. AFB1 is an important chemical carcinogen [3,34],
which is mainly metabolized by cytochrome P450 into
the genotoxic metabolic AFB1-epoxide that can bind to
DNA, causing the formation of AFB1-guanine adducts and
inducing DNA damage including base damage and oxida-
tive DNA damage that can be repair by NER pathway
[3,4,34].
While XPD protein, encoded by XPD gene, is a DNA-
dependent ATPase/helicase that is associated with the
TFIIH transcription-factor complex, and plays a role in
NER pathway. During NER, XPD participates in the open-
ing of the DNA helix to allow the excision of the DNA
fragment containing the damaged base [8,9]. There are
four described polymorphisms that induce amino acid
changes in the protein: in codons 199 (Ile to Met), 201
(His to Tyr), 312 (Asp to Asn) and 751 (Lys to Gln). The
first two are quite rare (~0.04%) in most population,
whereas codon 312 and 751 polymorphisms in conserved
region of XPD have been extensively studied [8-10]. Sev-
eral groups have done genotype-phenotype analyses with
these two polymorphisms and have shown that the vari-
ant allele genotypes are associated with low DNA repair
ability [11,12]. For example, Spitz, et al. [11] investigated
modulation of NER capacity by XPD codon 312 and 751
polymorphisms in lung cancer patients. They found that
those individuals carrying with XPD genotypes with
codon 312 Asn alleles or/and 751 Gln alleles showed
lower NER capacity than those with wild-type genotypes.
Rzeszowska-Wolny et al. [12] investigated effect of poly-
morphisms in this gene codon 312 and 751 on DNA dam-
age induced by gamma radiation and its repair in
lymphocytes in vitro. They found that XPD 312 Asn alleles
were associated with more radiation-induced Damage.
Recently, many studies have showed that there is associa-
tion between these two polymorphisms of XPD and DNA-
adducts levels [22,23], p53 gene mutation [14-17], and
cancers risk [13,18-30]. These results are controversial;
however, most studies have shown that XPD codon 751
Gln alleles and codon 312 Asn alleles are positively
related to high cancer risk [11,19,20,25-30]. In this study,
we did not found significant evidence for the effects of
XPD codon 312 polymorphism on HCC risk, but our data
supported that this gene codon 751 Gln alleles increased
the risk of AFB1-related HCC. Therefore, the possibility
that the XPD protein influences HCC risk through an
alternative pathway should not be ignored.
Interestingly, previous several studies have implied that
the genotypes of XPD codon 751 be able to interact with
environmental risk factors in the process of cancer devel-
opment [22,27,35]. For example, Terry, et al. [22] ana-
lyzed the association between XPD codon 751
polymorphism and breast cancer risk. They found this
polymorphism may interact with environmental expo-
sures and markers such as polycyclic aromatic hydrocar-
bon-DNA adducts and cigarette smoking in the breast
cancer development. In this study, we found that XPD
codon 751 polymorphism would be able to interact with
AFB1-exposure years in the process of AFB1-induced
HCC. Additionally, we also found some evidence of a
joint effects of the genotypes of XPD codon 751 and the
levels of AFB1-exposure, although the multiplicative
interaction term was not statistically significant.
Those results suggest that this polymorphism may alter
the normal protein function, and consequently may be
associated with a reduction in DNA repair capacity [8,9].
Thus, the DNA damage induced by AFB1 cannot be
repaired effectively and duly, consequently may induce
genic mutation such as p53 [14-17], and hepatocellular
canceration. Thus, XPD Lys751Gln polymorphism may
play a role in the carcinogenetic pathway of Guangxiese
HCC.
In this study, we stratified the analysis of XPD codon 751
genotypes by sex. This was done primarily because previ-
ous several studies had provided evidence that there
might be biological plausibility for gender differences in
DNA repair capacity [36-38]. Mayer et al. [36] reported a
decrease in double-strand break repair in women com-
pared with men. Similarly, Duval et al. [37] showed a
decrease in mismatch repair capacity and increased micro-
satellite instability for women compared with men. In
addition, findings from Kovtun et al. [38] suggest the pos-
sibility that X- or Y-encoded factors influence repair or
replication of DNA in the embryo. While our study
showed the XPD genotypes with codon 751 Gln alleles
had higher HCC risk among women than among men
(Pinteraction  < 0.01), which implied a decrease in NER
capacity and a increase cancer risk for women compared
with men. In support of aforementioned hypothesis,
recent several molecular epidemiology researches have
reported decreased DNA repair capacity, increased DNA-
adduct levels, and increased cancer risk for women com-
pared to men [11,27]. These findings could, therefore,
explained increased risk of HCC associated with the XPDBMC Cancer 2009, 9:400 http://www.biomedcentral.com/1471-2407/9/400
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genotypes with codon 751 Gln alleles among female pop-
ulation in our study.
Conclusion
In summary, to the best of our knowledge, this is the first
report to investigate association between XPD codon 312
and 751 polymorphisms and the risk of HCC for Guangxi
population from an high AFB1-exposure area. We find
evidence to suggest that the genotypes of XPD with codon
751 Gln alleles may increase the risk of AFB1-related HCC
and the NER pathway may play an important role in the
mechanism of action of this genotoxin. However, there
were several limitations to our study. Despite XPD poly-
morphisms analyzed, we did not analyze the genetic pol-
ymorphisms of other DNA repair genes involving in the
NER such as XPA, XPC, and so on [5]. Our findings were
based on relatively small numbers and limited by small
number subjects in part of the genotype strata. Therefore,
the more genes deserve further elucidation based on a
large sample and the combination of genes and AFB1
exposure.
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